Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting

Internal Medicine Journal

Volumn 37, Issue 4, 2007, Pages 247-250

  Osorio Sanchez, J A A ^a   Karapetis, C ^a   Koczwara, B ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Aprepitant; Audit; Chemotherapy; Nausea; Vomiting

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; APREPITANT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MESNA; NAVELBINE; OXALIPLATIN; SEROTONIN; SEROTONIN 3 ANTAGONIST;

ADD ON THERAPY; ADULT; AGED; ANOREXIA; ANTIEMETIC ACTIVITY; ARTICLE; BLOATING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HICCUP; HOSPITALIZATION; HUMAN; INDIGESTION; INJECTION SITE PAIN; LEIOMYOSARCOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VERTIGO;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; VOMITING;

EID: 33947428307     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01311.x     Document Type: Article

References (21)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-95.
2. de Boer-Dennert M, de Wit R, Schmitz PIM, Djontono J, Beurden V, Stoter G et al. Patient perceptions of the side effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997; 7: 1055-61.
3. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990's: impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994; 2: 286-92.
4. Passik SD, Kirsch KL, Rosenfeld B, McDonald MV, Theobald DE. The changeable nature of patient's fears regarding chemotherapy. Implications for palliative care. J Pain Symptom Manage 2001; 21: 113-20.
5. Laszlo J, Lucas VSJ. Emesis as a critical problem in chemotherapy. N Engl J Med 1981; 305: 948-9.
6. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
7. Roila F, Bracardia S, Tonato M, Maranglo M, Bella M, Donati D et al. Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol 1990; 2: 268-72.
8. Hesketh P. Management of cisplatin-induced delayed emesis. Oncology 1996; 53 Suppl. 1: 78-85.
9. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14.
10. Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology 1996; 53 Suppl. 1: 86-91.
11. Campos D, Pereira JR, Reinhardt R, Carracedo C, Poli S, Vogel C et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-0869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67.
12. Hesketh P, Grunberg S, Gralla R, Warr DG, Roila F, deWit R et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
13. Navari R, Reinhart R, Gralla, Kris G, Hesketh PJ, Khojasteh A et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999; 340: 190-95.
14. Moore SG, Tumeh JW, Wojtanowski S, Flowers CR. Assessing the cost-effectiveness of adding aprepitant to the ASCO standard for prophylaxis of chemotherapy induced nausea and vomiting [abstract no 6009]. Proc Am Soc Clin Oncol 2006.
15. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, Mar 31, 2003 (http://ctep.cancer.gov), Publish Date: June 10, 2003.
16. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of post Chemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997; 15:116-23.
17. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Cancer 1989; 64: 1117-22.
18. Warr D, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-30.
19. de Wit R, Schmitz PIM, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS et al. Analysis of cumulative probabilities show that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14: 644-51.
20. de Wit R, van den Berg H, Burghouts J, Nortier J, Slee P, Rodenburg C et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998; 77: 1487-91.
21. Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001; 19: 2091-7.